Kahn C R, Levy A G, Gardner J D, Miller J V, Gorden P, Schein P S
N Engl J Med. 1975 May 1;292(18):941-5. doi: 10.1056/NEJM197505012921803.
Two patients with pancreatic cholera and islet-cell carcinoma were treated with intra-arterial streptozotocin. Before therapy, they had stool volumes from 2 to 8 liters per day and required 200 to 800 mEq per day of supplemental potassium. After three to five doses of streptozotocin (1.5 per square meter), both stool volume and number and size of hepatic metastases decreased markedly. One patient has had normally formed stools for 12 months; the other had a 90 per cent reduction in stool volume for 13 months with additional therapy. Both patients' serum potassium returned to normal without need for supplementation. Jejunal adenylate cyclase activity was normal in both, and plasma vasoactive intestinal peptide was detectable in only one. After chemotherapy, these findings showed no consistent change. Pharmacologic studies suggest that arterial administration increased either tumor or hepatic extraction (or both) of streptozotocin by two times and decreased renal exposure to this nephrotoxic drug by one third.
两名患有胰性霍乱和胰岛细胞癌的患者接受了动脉内链脲佐菌素治疗。治疗前，他们每天的粪便量为2至8升，每天需要补充200至800毫当量的钾。在给予三至五剂链脲佐菌素（每平方米1.5克）后，粪便量以及肝转移灶的数量和大小均显著减少。一名患者已正常排便12个月；另一名患者在接受额外治疗后，粪便量减少了90%，持续了13个月。两名患者的血清钾均恢复正常，无需补充。两人的空肠腺苷酸环化酶活性均正常，仅在一人中检测到血浆血管活性肠肽。化疗后，这些结果未显示出一致的变化。药理学研究表明，动脉给药使链脲佐菌素的肿瘤摄取或肝脏摄取（或两者）增加了两倍，并使肾脏接触这种肾毒性药物的量减少了三分之一。
